Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on December 15, 2025. The filing was submitted on December 16, 2025. The Company acted through BNP Paribas SA as the broker to purchase ordinary shares of 31½ pence each as part of an existing share buyback programme.
Key Financial Metrics and Transaction Details
The filing details a specific share repurchase event rather than full-period financial results. Key metrics for the transaction are as follows:
- Shares Purchased: 230,000 ordinary shares.
- Price Range: Lowest price paid was 1,810.50p; highest price paid was 1,838.00p.
- Average Price: Volume-weighted average price paid was 1,825.73p.
- Trading Venues: Purchases were executed across BATE, CHIX, and XLON (London Stock Exchange).
- Treasury Holdings: Following this purchase, the Company holds 239,086,577 ordinary shares in treasury.
- Shares in Issue: 4,076,354,506 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.87% of total voting rights.
Material Changes and Programme Progress
This purchase was effected pursuant to a non-discretionary agreement entered into with the broker on September 30, 2025. Since the inception of this specific agreement on September 30, 2025, the Company has purchased a total of 13,621,733 ordinary shares. The filing does not provide comparative financial data (revenue, profit, or cash flow) for the period, as it is a disclosure of a capital transaction.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the Company's Annual Report on Form 20-F for 2024 and its Q3 Results for 2025. No new guidance or management commentary regarding operational outlook is provided in this specific filing.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since September 30, 2025 (13,621,733 shares).
- Confirm the current percentage of voting rights held in treasury (5.87%) against regulatory thresholds.
- Review the volume-weighted average price (1,825.73p) against the prevailing market price on December 15, 2025.
- Check the total number of shares in issue (4,076,354,506) for dilution or EPS calculation purposes.
- Refer to the referenced Form 20-F (2024) and Q3 2025 results for detailed risk factors and financial performance context.